| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 629 companies in the Biotechnology industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 4, 2026 | ADTX Aditxt, Inc. | Hrt Financial LP45 | 10% Owner | Buy | 843,622 | $0.08 | $64,115.27 | -249.4% | - | - | |
| Jun 4, 2026 | SMMT Summit Therapeutics Inc. | Duggan Robert W76 | Co-chief Executive Officer | Buy | 100,000 | $14.60 | $1,460,000.00 | +0.4% | - | - | |
| Jun 3, 2026 | APGE Apogee Therapeutics, Inc. | Dambkowski Carl48 | Chief Medical Officer | Sell | 5,500 | $78.71 | $432,905.00 | -2.6% | - | - | |
| Jun 3, 2026 | SYRE Spyre Therapeutics, Inc. | Sloan Sheldon | Chief Medical Officer | Sell | 8,333 | $75.00 | $624,975.00 | -100% | - | - | |
| Jun 3, 2026 | QURE Uniqure N.V. | Kaye Jack48 | Director | Sell | 2,645 | $30.01 | $79,376.45 | -11.5% | - | - | |
| Jun 3, 2026 | CRBP Corbus Pharmaceuticals Holdings, Inc. | Saxena Nishant C | Chief Business Officer | Buy | 13,500 | $7.50 | $101,218.50 | +10.5% | - | - | |
| Jun 2, 2026 | JANX Janux Therapeutics, Inc. | Doyle Janeen Noel | Chief Corp. &Bus. Dev. Ofcr | Sell | 4,059 | $14.03 | $56,943.71 | -5.1% | - | - | |
| Jun 2, 2026 | NRIX Nurix Therapeutics, Inc. | Ring Christine77 | Chief Legal Officer | Sell | 8,148 | $16.60 | $135,252.73 | -37.5% | - | - | |
| Jun 2, 2026 | ASND Ascendis Pharma A/s | Smith Scott Thomas | EVP &Chief Financial Officer | Buy | 100 | $219.00 | $21,900.00 | +2.3% | - | - | |
| Jun 2, 2026 | HYPD Hyperion Defi, Inc. | Jung Hyunsu | See Remarks | Buy | 8,000 | $3.70 | $29,580.00 | +0.1% | - | - | |
| Jun 2, 2026 | AXSM Axsome Therapeutics, Inc. | Coleman Mark | Director | Sell | 17,537 | $229.20 | $4,019,470.43 | -14.2% | - | - | |
| Jun 2, 2026 | AUPH Aurinia Pharmaceuticals Inc. | Tang Kevin86 | Chief Executive Officer | Buy | 814,606 | $15.29 | $12,455,227.01 | +1.3% | - | - | |
| Jun 2, 2026 | CVKD Cadrenal Therapeutics, Inc. | Pham Quang X49 | CEO And Chairman | Sell | 652 | $4.72 | $3,074.57 | -0.2% | - | - | |
| Jun 1, 2026 | SYRE Spyre Therapeutics, Inc. | Turtle Cameron | Chief Executive Officer | Sell | 15,000 | $70.43 | $1,056,486.02 | -0.8% | - | - | |
| Jun 1, 2026 | OBIO Orchestra Biomed Holdings, Inc. | Sherman Darren77 | See Remarks | Sell | 15,000 | $3.87 | $58,050.00 | -1.3% | - | - | |
| Jun 1, 2026 | MDWD Mediwound Ltd. | Fox David Morton | Director | Buy | 3,537 | $14.11 | $49,900.57 | +5.9% | - | - | |
| Jun 1, 2026 | SNSE Sensei Biotherapeutics, Inc. | Cambrian Biopharma Inc | 10% Owner | Sell | 25,000 | $20.02 | $500,542.64 | -8.7% | - | - | |
| Jun 1, 2026 | MIRM Mirum Pharmaceuticals, Inc. | Peetz Christopher45 | Chief Executive Officer | Sell | 30,000 | $95.84 | $2,875,103.34 | -2.4% | - | - | |
| Jun 1, 2026 | CYTK Cytokinetics, Incorporated | Parshall B Lynne74 | Director | Sell | 5,000 | $74.08 | $370,400.00 | -24.1% | - | - | |
| Jun 1, 2026 | XERS Xeris Biopharma Holdings, Inc. | Hecht Beth47 | See Remarks | Sell | 16,667 | $6.06 | $100,982.02 | -1.4% | - | - | |
| Jun 1, 2026 | VIR Vir Biotechnology, Inc. | Sabatini Brent | SVP, Chief Accounting Officer | Sell | 379 | $9.45 | $3,581.55 | -0.6% | - | - | |
| Jun 1, 2026 | MDGL Madrigal Pharmaceuticals, Inc. | Soergel David | Chief Medical Officer | Sell | 1,042 | $495.74 | $516,561.08 | -9.4% | - | - | |
| Jun 1, 2026 | MAIA Maia Biotechnology, Inc. | Vitoc Vlad | Chief Executive Officer | Buy | 72,700 | $1.39 | $100,885.79 | +8.0% | - | - | |
| Jun 1, 2026 | CTNM Contineum Therapeutics, Inc. | Lorrain Daniel S.68 | Chief Scientific Officer | Sell | 4,170 | $13.16 | $54,862.19 | -2.9% | - | - | |
| Jun 1, 2026 | VIR Vir Biotechnology, Inc. | Napolitano Janet57 | Director | Sell | 3,200 | $9.45 | $30,240.00 | -13.1% | - | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.